Modulating HtrA3 activity using 6G6 or 10H10 in pathological conditions such as preeclampsia, arthritis and tumor progression [1], [10], [11], [15], [16] would provide novel therapeutic applications. The gene discussed is HTRA3; the disease is arthritic joint disease.